PYLARIFY® PET/CT was well tolerated across multiple studies including 593 men with PCa2

Adverse reactions that occurred in >0.5% of
men who received PYLARIFY® (n=593)*

Table showing adverse reaction rates from PYLARIFY® clinical trials. Table showing adverse reaction rates from PYLARIFY® clinical trials.

*In addition, a hypersensitivity reaction was reported in 1 patient (0.2%) with a history of allergic reactions.

REVIEW CASE STUDIES FROM PYLARIFY® CLINICAL TRIALS

LEARN MORE

PCa=prostate cancer.

INDICATION

PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

References

  1. FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.
  2. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.